Resolve Therapeutics

Executive Summary

Resolve Therapeutics is a privately held biotech company developing a novel class of biologics that combine RNase/DNase enzymes with antibody Fc domains to degrade extracellular RNA, DNA, and neutrophil extracellular traps (NETs). This approach aims to resolve inflammation in autoimmune diseases such as Sjögren’s syndrome, systemic lupus erythematosus, and critical care settings without suppressing the immune system. By targeting the root cause of tissue damage—extracellular nucleic acids and NETs—the company’s platform offers a potentially safer and more targeted alternative to broad immunosuppressants. Founded in 2015 and based in Seattle, Resolve is currently advancing its lead candidate in Phase 2 clinical trials for Sjögren’s disease. The company’s near-term value hinges on the readout of its Phase 2 study in Sjögren’s syndrome, which could provide proof-of-concept for its mechanism and pave the way for Phase 3 development. Additionally, expansion into lupus and critical care represents significant upside, though these programs are earlier stage. Given the high unmet need in Sjögren’s and lupus and the differentiated mechanism, Resolve Therapeutics is an intriguing but high-risk opportunity. The next 12–18 months will be pivotal as clinical data emerge and potential partnerships materialize.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Topline Data for Sjögren's Syndrome45% success
• H1 2027Initiation of Phase 2 Trial in Lupus30% success